fincash logo SOLUTIONS
EXPLORE FUNDS
CALCULATORS
LOG IN
SIGN UP

Fincash » Mutual Funds » Nippon India PHARMA Fund

Nippon India PHARMA Fund - G

NAV  ₹273.998 ↓ -0.31  (-0.11 %) as on 2 Feb 23

Scheme Objective

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

Nippon India Pharma Fund is a Equity - Sectoral fund launched on 5 Jun 04. It is a fund with High risk and has given a CAGR return of 19.4% since its launch.  Ranked 35 in Sectoral category.  Return for 2022 was -9.9% , 2021 was 23.9% and 2020 was 66.4% .

Below is the key information for Nippon India Pharma Fund

NAV as on 2 Feb 23₹273.998 ↓ -0.31  (-0.11 %)
Net Assets (AUM) as on 31 Dec 2022 ₹4,563 Cr.
Launch Date5 Jun 2004
CategoryEquity - Sectoral
Rating
TypeOpen Ended Fund
RiskHigh
AMCNippon Life Asset Management Ltd.
Alpha Ratio0.8
Expense Ratio1.96 %
Sharpe Ratio-0.979
Information Ratio0.61
BenchmarkNot Available
Min Investment ₹5,000
Min SIP Investment ₹100
Exit Load 0-1 Years (1%),1 Years and above(NIL)

Returns

Annual Compounded Returns

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 2 Feb 23

DurationReturns
1 Month -2.6%
3 Month -7.2%
6 Month -0.6%
1 Year -6.8%
3 Year 20.6%
5 Year 14.3%
10 Year
15 Year
Since launch 19.4%

Historical Annual Returns

Historical performance (Yearly) on absolute basis

YearReturns
2022 -9.9%
2021 23.9%
2020 66.4%
2019 1.7%
2018 3.6%
2017 7.6%
2016 -10.6%
2015 19.4%
2014 49.5%

Growth of 10k Over Years

DateValue
31 Jan 18₹10,000
31 Jan 19₹10,569
31 Jan 20₹10,881
31 Jan 21₹16,979
31 Jan 22₹19,963
31 Jan 23₹19,197
Nippon India PHARMA Fund Growth 10k Chart

Asset Allocation

Asset ClassValue
Cash0.45%
Equity99.55%
Nippon India PHARMA Fund Asset Allocation

Sector Allocation

SectorValue
Health Care99.55%
Nippon India PHARMA Fund Equity Allocation

Top Securities Holdings / Portfolio

Holdings/Securities

NameGlobal IndustryHoldingValueQuantity
Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 09 | SUNPHARMA
Drug Manufacturers - Specialty & Generic14%₹657 Cr6,556,349
↓ -444,627
Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 30 Jun 11 | DRREDDY
Drug Manufacturers - Specialty & Generic8%₹375 Cr885,000
Cipla Ltd (Healthcare)
Equity, Since 31 May 08 | CIPLA
Drug Manufacturers - General8%₹366 Cr3,400,000
↓ -300,000
Lupin Ltd (Healthcare)
Equity, Since 31 Aug 08 | LUPIN
Drug Manufacturers - Specialty & Generic7%₹330 Cr4,500,025
Abbott India Ltd (Healthcare)
Equity, Since 31 May 11 | ABBOTINDIA
Drug Manufacturers - General6%₹276 Cr129,321
Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Sep 20 | APOLLOHOSP
Medical Care Facilities5%₹233 Cr520,772
Narayana Hrudayalaya Ltd (Healthcare)
Equity, Since 30 Jun 17 | NH
Medical Care Facilities5%₹227 Cr2,981,429
Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB
Drug Manufacturers - Specialty & Generic5%₹222 Cr650,000
Torrent Pharmaceuticals Ltd (Healthcare)
Equity, Since 30 Sep 20 | TORNTPHARM
Drug Manufacturers - Specialty & Generic4%₹171 Cr1,100,857
↓ -200,000
Fortis Healthcare Ltd (Healthcare)
Equity, Since 31 Aug 18 | FORTIS
Medical Care Facilities4%₹160 Cr5,600,000
1 - 10 of 34
Ready to Invest?
Talk to our investment specialist
Disclaimer:
By submitting this form I authorize Fincash.com to call/SMS/email me about its products and I accept the terms of Privacy Policy and Terms & Conditions.

Fund Managers

NameSinceTenure
Sailesh Raj Bhan1 Apr 0517.76 Yr.
Kinjal Desai25 May 184.61 Yr.
Akshay Sharma1 Dec 220.08 Yr.

Custodians

CompanyAddress
Deutsche Bank AGDeutsche Bank AG,Kodak House, 22, D.N. Road,

Registrar & Transfer Agent

KFin Technologies Ltd
AddressKFin Technologies Pvt. Ltd,,1D/D Extension 2, Valmiki Chowk,,Gandhi Nagar,
FAX91-40-23311968
Emailmailmanager@karvy.com

Administrator Companies

CompanyAddress
Nippon India Mutual Fund9th Floor, Crescenzo, C-38 & 39,,G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400051

Auditors

CompanyAddress
Haribhakti & Co. Chartered Accountants42, Free Press House,4th Floor,,215, Nariman Point,

All Plan & Options

Fund and PlanNAV6 Month1 Year3 Year5 Year
Nippon India Pharma Fund
Normal Dividend, Payout
₹76.0841
↓ -0.09
-0.65 %-2.73 %25.06 %16.57 %
Nippon India Pharma Fund
Normal Dividend, Reinvestment
₹76.0841
↓ -0.09
-0.65 %-2.73 %25.06 %16.57 %
Nippon India Pharma Fund
Growth
₹273.998
↓ -0.31
-0.65 %-6.79 %20.61 %14.3 %
Data as on 2 Feb 23

Disclaimer:
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data.